Drug data last refreshed 21h ago · AI intelligence enriched 2w ago
TEEBACIN (aminosalicylate sodium) is an oral tablet antitubercular agent approved in 1950 for treating tuberculosis, particularly drug-resistant TB. It works as a prodrug that is converted to aminosalicylic acid in vivo to inhibit mycobacterial folate synthesis. This legacy small-molecule therapy remains relevant in combination regimens for multidrug-resistant tuberculosis (MDR-TB).
As a legacy product approaching loss of exclusivity with moderate competitive pressure (30/100), the brand team is likely optimizing manufacturing efficiency and lifecycle management rather than pursuing aggressive expansion.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Working on TEEBACIN offers career exposure in manufacturing excellence and operational leadership within a legacy portfolio. Roles are concentrated in supply chain, quality, and process optimization rather than commercial growth or clinical innovation, making this a niche opportunity for professionals seeking deep technical expertise in pharma operations.
Worked on TEEBACIN at Century Therapeutics? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
3 open roles linked to this drug